Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

A new urology lab with advanced diagnostic testing is up and running at UPMC St. Margaret Hospital to deal with a slow but ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

The Prostate Cancer Market is set to grow from USD 11.7 Billion in 2022 to USD 21.6 Billion by 2031, driven by rising cases in targeted therapies. The U.S. Prostate Cancer Market is expanding rapidly ...

A tool developed by a scientist at UVA’s School of Nursing can help prostate cancer patients make important decisions when it comes to treatment options.

"Cancer changes you and everyone around you. That’s not a cliché. For me, it brought anxiety, urgency and openness." ...

The Philadelphia Conquering Cancer Coalition aims to remove barriers and improve communication and collaboration between ...

The Maine Senate's refusal to waive the waiting period between requesting and receiving life-ending prescriptions is ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

Please see this procedure for additional information. Prostate cancer treatment has entered the robotics age. Using advanced robotic technology, Johns Hopkins surgeons can see the prostate in 3-D, ...

There may be hopeful news ahead for families with a history of breast and ovarian cancer. Researchers from the University of ...